John Overdeck’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-153,459
| Closed | -$3.09M | – | 5259 |
|
|
2026
Q1 | $3.09M | Buy |
+153,459
| New | +$2.47M | ﹤0.01% | 2417 |
|
|
2025
Q1 | – | Sell |
-13,463
| Closed | -$114K | – | 3355 |
|
|
2024
Q4 | $114K | Sell |
13,463
-13,487
| -50% | -$140K | ﹤0.01% | 2951 |
|
|
2024
Q3 | $312K | Sell |
26,950
-1,247
| -4% | -$15.7K | ﹤0.01% | 2654 |
|
|
2024
Q2 | $332K | Sell |
28,197
-163,502
| -85% | -$1.91M | ﹤0.01% | 2549 |
|
|
2024
Q1 | $2.27M | Buy |
191,699
+25,940
| +16% | +$346K | 0.01% | 1395 |
|
|
2023
Q4 | $2.03M | Buy |
165,759
+61,965
| +60% | +$564K | ﹤0.01% | 1530 |
|
|
2023
Q3 | $1,000K | Buy |
103,794
+4,632
| +5% | +$47.3K | ﹤0.01% | 1930 |
|
|
2023
Q2 | $892K | Buy |
99,162
+44,797
| +82% | +$413K | ﹤0.01% | 2002 |
|
|
2023
Q1 | $427K | Buy |
54,365
+36,949
| +212% | +$276K | ﹤0.01% | 2278 |
|
|
2022
Q4 | $118K | Buy |
+17,416
| New | +$93.3K | ﹤0.01% | 2487 |
|
|
2022
Q3 | – | Sell |
-37,453
| Closed | -$369K | – | 2642 |
|
|
2022
Q2 | $369K | Buy |
+37,453
| New | +$413K | ﹤0.01% | 1938 |
|
|
2022
Q1 | – | Sell |
-97,592
| Closed | -$1.29M | – | 3505 |
|
|
2021
Q4 | $1.29M | Sell |
97,592
-25,051
| -20% | -$399K | ﹤0.01% | 2330 |
|
|
2021
Q3 | $2.14M | Buy |
122,643
+65,765
| +116% | +$1.33M | ﹤0.01% | 1924 |
|
|
2021
Q2 | $1.36M | Sell |
56,878
-23,795
| -29% | -$623K | ﹤0.01% | 2207 |
|
|
2021
Q1 | $2.07M | Buy |
80,673
+52,277
| +184% | +$1.37M | 0.01% | 1685 |
|
|
2020
Q4 | $539K | Buy |
+28,396
| New | +$487K | ﹤0.01% | 2462 |
|
|
2020
Q3 | – | Sell |
-27,262
| Closed | -$330K | – | 3318 |
|
|
2020
Q2 | $330K | Buy |
+27,262
| New | +$290K | ﹤0.01% | 2310 |
|
|
2019
Q3 | – | Sell |
-13,696
| Closed | -$303K | – | 3635 |
|
|
2019
Q2 | $303K | Buy |
+13,696
| New | +$321K | ﹤0.01% | 2855 |
|
|
2018
Q4 | – | Sell |
-12,740
| Closed | -$282K | – | 3268 |
|
|
2018
Q3 | $282K | Buy |
+12,740
| New | +$172K | ﹤0.01% | 2806 |
|
Other funds holding KALV
John Overdeck's KALV Position: Q2 2026 in Review
John Overdeck sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 153,459 shares — an estimated $3.09M sold.
John Overdeck first reported a position in KALV in Q3 2018 and held it in 19 quarters. The position peaked at $3.09M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- John Overdeck reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- John Overdeck sold 153,459 KalVista Pharmaceuticals shares in Q2 2026, an estimated $3.09M.
- John Overdeck first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 19 quarters.
- John Overdeck's KalVista Pharmaceuticals position peaked at $3.09M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.